Cadrenal Therapeutics, Inc. (NASDAQ:CVKD – Free Report) – Equities research analysts at Zacks Small Cap issued their Q3 2024 earnings per share estimates for shares of Cadrenal Therapeutics in a report released on Monday, September 16th. Zacks Small Cap analyst D. Bautz anticipates that the company will post earnings per share of ($2.18) for the quarter. The consensus estimate for Cadrenal Therapeutics’ current full-year earnings is ($6.00) per share. Zacks Small Cap also issued estimates for Cadrenal Therapeutics’ Q4 2024 earnings at ($2.18) EPS, FY2024 earnings at ($8.17) EPS, FY2025 earnings at ($2.90) EPS and FY2026 earnings at ($2.20) EPS.
Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($2.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($19.04) by $16.79.
View Our Latest Analysis on CVKD
Cadrenal Therapeutics Stock Up 1.4 %
Shares of NASDAQ CVKD opened at $11.98 on Wednesday. The stock has a market capitalization of $191.78 million, a price-to-earnings ratio of -38.65 and a beta of 1.74. Cadrenal Therapeutics has a 1 year low of $5.40 and a 1 year high of $32.55.
Cadrenal Therapeutics Company Profile
Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.
Featured Articles
- Five stocks we like better than Cadrenal Therapeutics
- CD Calculator: Certificate of Deposit Calculator
- How Much Can You Make in Stocks in One Month?
- Ride Out The Recession With These Dividend Kings
- This Is the Top Large-Cap Stock Insiders Are Buying
- 3 Fintech Stocks With Good 2021 Prospects
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Receive News & Ratings for Cadrenal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cadrenal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.